Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义

doi:10.3969/j.issn.1004-616x.2019.02.001

癌变·畸变·突变 ›› 2019, Vol. 31 ›› Issue (2): 89-95.doi: 10.3969/j.issn.1004-616x.2019.02.001

• 论著 • 下一篇

Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义

朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀

国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院分子肿瘤学国家重点实验室, 癌发生及预防分子机理北京市重点实验室, 北京 100021

收稿日期:2018-12-28 修回日期:2019-02-25 出版日期:2019-03-30 发布日期:2019-03-30
通讯作者: 肖汀,E-mail:xiaot@cicams.ac.cn E-mail:xiaot@cicams.ac.cn
作者简介:朱嘉微,E-mail:504092093@qq.com
基金资助:
中国医学科学院医学与健康科技创新项目（2016-I2M-1-001）

Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood

ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting

State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2018-12-28 Revised:2019-02-25 Online:2019-03-30 Published:2019-03-30

摘要/Abstract

摘要： 目的：检测S期激酶相关蛋白1（Skp1）在非小细胞肺癌（NSCLC）组织和外周血中的表达水平并探讨其临床意义。方法：采用Western blot检测34例NSCLC组织及相应癌旁组织中Skp1蛋白的表达水平。采用组织芯片和免疫组织化学染色检测Skp1在86例NSCLC组织及相应癌旁组织中的表达情况，并分析Skp1蛋白的表达与NSCLC临床病理指标及患者预后的关系。采用酶联免疫吸附试验（ELISA）检测39例NSCLC患者及27例健康人血浆中的Skp1蛋白水平。结果：Western blot和免疫组化法分析结果显示Skp1蛋白在NSCLC组织中的表达水平均显著高于相应癌旁组织（P < 0.001）。ELISA法分析结果显示NSCLC病人血浆中的Skp1蛋白表达水平显著高于健康人群（P=0.003）。Kaplan-Meier单因素生存分析显示Skp1蛋白在NSCLC组织中的高表达与中晚期（Ⅱ+Ⅲ） NSCLC患者的不良预后显著相关（P=0.001），多因素Cox回归分析显示Skp1蛋白能够作为影响中晚期（Ⅱ+Ⅲ） NSCLC患者预后的独立危险因素。Skp1蛋白表达水平与病理类型、临床分期、分化程度、淋巴结转移等因素无显著相关关系（P > 0.05）。结论：Skp1蛋白在NSCLC患者中高表达，并且Skp1蛋白在NSCLC组织中的高表达与中晚期（Ⅱ+Ⅲ） NSCLC患者的不良预后显著相关，可作为中晚期NSCLC患者预后的独立危险因素。

关键词: Skp1, 非小细胞肺癌, 预后, 危险因素

Abstract: OBJECTIVE:To detect the protein expression of Skp1(S-phase kinase-associated protein 1) in non-small cancer lung cancer (NSCLC) tissues and peripheral blood,and to explore its clinical significance.METHODS:Expressions of Skp1 protein in 34 NSCLC tissues and 34 adjacent tissues were detected by Western Blot.In addition,the expressions in 86 NSCLC tissues and 86 adjacent tissues were detected by tissue microarray and immunohistochemical staining method.The plasma expression level of Skp1 in 39 NSCLC patients and 27 healthy person was detected by ELISA (enzyme linked immunesorbent assay).The relationships between Skp1 expression with clinicopathological parameters and prognosis of NSCLC patients were analyzed.RESULTS:The expression level of Skp1 protein in NSCLC tissues was significantly higher than that in adjacent tissues by both Western blot and immunohistochemical staining methods (P < 0.01).The plasma levels in NSCLC patients were significantly higher than that in healthy person (P=0.003).The simple factors analyses show that over-expression of Skp1 protein in NSCLC tissues was significantly associated with poor prognosis in the middle to late cancer stages (Ⅱ+Ⅲ)(P=0.001),and the multiple factors Cox regression analysis showed that Skp1 protein could be used as the independent risk factors for the middle to late stages (Ⅱ+Ⅲ).The expression of Skp1 protein had no correlation with pathological type,clinical stage,pathological grade,lymph node metastasis and other factors (P > 0.05).CONCLUSION:Skp1 protein was over-expressed in NSCLC tissues and plasma from patients,and the over-expression of Skp1 protein in NSCLC tissues was significantly associated with poor prognosis in the middle to late cancer stages (Ⅱ+Ⅲ).Therefore,the over-expression can be considered for use as an independent risk factor for the middle to late stages among NSCLC patients.

Key words: Skp1, non-small cell lung cancer, prognosis, risk factors

中图分类号:

R730.7

朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.

ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.

参考文献

[1] BLANDIN KNIGHT S,CROSBIE P A,BALATA H,et al. Progress and prospects of early detection in lung cancer[J]. Open Biol,2017,7(9):170070.
[2] TARTARI R F,ULBRICH-KULCZYNSKI J M,FILHO A F. Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients[J]. Oncol Lett,2013,5(3):1063-1067.
[3] HUSSAIN M,LU Y,LIU Y Q,et al. Skp1:Implications in cancer and SCF-oriented anti-cancer drug discovery[J]. Pharmacol Res,2016,111:34-42.
[4] KUHN D J,CHEN Q,VOORHEES P M,et al. Potent activity of carfilzomib,a novel,irreversible inhibitor of the ubiquitin-proteasome pathway,against preclinical models of multiple myeloma[J]. Blood,2007,110(9):3281-3290.
[5] RICHARDSON P G,SONNEVELD P,SCHUSTER M W,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med,2005,352(24):2487-2498.
[6] HERSHKO A,CIECHANOVER A. The ubiquitin system[J]. Annu Rev Biochem,1998,67:425-479.
[7] YOSHIDA Y,MURAKAMI A,TANAKA K. Skp1 stabilizes the conformation of F-box proteins[J]. Biochem Biophys Res Commun,2011,410(1):24-28.
[8] SKAAR J R,PAGAN J K,PAGANO M. Mechanisms and function of substrate recruitment by F-box proteins[J]. Nat Rev Mol Cell Biol,2013,14(6):369-381.
[9] GSTAIGER M,MARTI A,KREK W. Association of human SCF(SKP2) subunit p19(SKP1) with interphase centrosomes and mitotic spindle poles[J]. Exp Cell Res,1999,247(2):554-562.
[10] CHANDRA DANTU S,NATHUBHAI KACHARIYA N,KUMAR A. Molecular dynamics simulations elucidate the mode of protein recognition by Skp1 and the F-box domain in the SCF complex[J]. Proteins,2016,84(1):159-171.
[11] BAI C,SEN P,HOFMANN K,et al. Skp1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif,the F-box[J]. Cell,1996,86(2):263-274.
[12] LIU Y Q,WANG X L,CHENG X,et al. Skp1 in lung cancer:clinical significance and therapeutic efficacy of its small molecule inhibitors[J]. Oncotarget,2015,6(33):34953-34967.
[13] WANG Z,LIU P,INUZUKA H,et al. Roles of F-box proteins in cancer[J]. Nat Rev Cancer,2014,14(4):233-247.
[14] REMMELE W,STEGNER H E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue[J]. Pathologe,1987,8(3):138-140.
[15] WANG X,ZHANG S,ZHANG T,et al. Prognostic values of F-box members in breast cancer:an online database analysis and literature review[J]. Biosci Rep,2018. pii:BSR20180949.
[16] YU Z K,GERVAIS J L,ZHANG H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins[J]. Proc Natl Acad Sci USA,1998,95(19):11324-11329.
[17] XU M,YANG X,ZHAO J,et al. High expression of Cullin1 indicates poor prognosis for NSCLC patients[J]. Pathol Res Pract,2014,210(7):397-401.
[18] HUANG Y F,ZHANG Z,ZHANG M,et al. CUL1 promotes breast cancer metastasis through regulating EZH2-induced the autocrine expression of the cytokines CXCL8 and IL11[J]. Cell Death Dis,2018,10(1):2.
[19] KIMBREL E A,KUNG A L. The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity[J]. J Biol Chem,2009,284(19):13033-13044.
[20] WANG J Y,LIU G Z,WILMOTT J S,et al. Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress[J]. Cancer Res,2017,77(22):6226-6239.
[21] TAKANAMI I. The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer[J]. Oncol Rep,2005,13(4):727-731.
[22] ZHANG Y,ZVI Y S,BATKO B,et al. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma[J]. Sci Rep 2018,8(1):14294.
[23] DING L,LI R,SUN R,et al. S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells[J]. Cell Cycle,2017,16(16):1547-1555.
[24] DING L,LI R,HAN X,et al. Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells[J]. Oncol Rep,2017,38(2):933-940.
[25] LIU W,WANG Y,ZHANG C,et al. Cullin1 is up-regulated and associated with poor patients' survival in hepatocellular carcinoma[J]. Int J Clin Exp Pathol,2015,8(4):4001-4007.
[26] MIGITA K,TAKAYAMA T,MATSUMOTO S,et al. Prognostic impact of RING box protein-1(RBX1) expression in gastric cancer[J]. Gastric Cancer,2014,17(4):601-609.
[27] RUAN D,HE J,LI C F,et al. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist[J]. Oncogene,2017,36(30):4299-4310.

Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义

Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[8]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[9]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[10]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[11]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[12]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[13]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[14]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[15]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.